Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
2020 · Journal for ImmunoTherapy of Cancer · 158 citations
https://doi.org/10.1136/jitc-2020-001240
X
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
163
Papers
3.5K
Citations
29
h-index
58
i10-index
Xiaofeng Wu is an academic researcher from Chinese Academy of Medical Sciences & Peking Union Medical College. The author has contributed to research in topics: Cancer-related molecular mechanisms research & RNA modifications and cancer & Cholangiocarcinoma and Gallbladder Cancer Studies. The author has an h-index of 29, co-authored 139 publications.
ORCID: 0000-0003-4501-1101Papers by this author
worksFluvoxamine alleviates bleomycin-induced lung fibrosis via regulating the cGAS-STING pathway
2022 · Pharmacological Research · 63 citations
https://doi.org/10.1016/j.phrs.2022.106577
The genomic landscape of cholangiocarcinoma reveals the disruption of post-transcriptional modifiers
2022 · Nature Communications · 62 citations
https://doi.org/10.1038/s41467-022-30708-7
Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study
2022 · Frontiers in Oncology · 47 citations
https://doi.org/10.3389/fonc.2022.909035
A Dual‐Response DNA Origami Platform for Imaging and Treatment of Sepsis‐Associated Acute Kidney Injury
2025 · Advanced Science · 13 citations
https://doi.org/10.1002/advs.202416330
Robot-assisted single-port retroperitoneal partial nephrectomy with a novel purpose-built single-port robotic system with deformable surgical instruments
2024 · World Journal of Urology · 12 citations
https://doi.org/10.1007/s00345-024-04827-3
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat